AU2021303440B2 - 1-(1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl)-pyrrolidine-2-carbonitrile - Google Patents

1-(1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl)-pyrrolidine-2-carbonitrile

Info

Publication number
AU2021303440B2
AU2021303440B2 AU2021303440A AU2021303440A AU2021303440B2 AU 2021303440 B2 AU2021303440 B2 AU 2021303440B2 AU 2021303440 A AU2021303440 A AU 2021303440A AU 2021303440 A AU2021303440 A AU 2021303440A AU 2021303440 B2 AU2021303440 B2 AU 2021303440B2
Authority
AU
Australia
Prior art keywords
compound
formula
disease
pyrrolidine
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021303440A
Other languages
English (en)
Other versions
AU2021303440A1 (en
Inventor
Roger PRADES COSANO
Teresa TARRAGÓ CLUA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Accure Therapeutics SL
Original Assignee
Accure Therapeutics SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Accure Therapeutics SL filed Critical Accure Therapeutics SL
Publication of AU2021303440A1 publication Critical patent/AU2021303440A1/en
Application granted granted Critical
Publication of AU2021303440B2 publication Critical patent/AU2021303440B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
AU2021303440A 2020-07-07 2021-07-06 1-(1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl)-pyrrolidine-2-carbonitrile Active AU2021303440B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20382606 2020-07-07
EP20382606.0 2020-07-07
PCT/EP2021/068577 WO2022008477A1 (en) 2020-07-07 2021-07-06 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile

Publications (2)

Publication Number Publication Date
AU2021303440A1 AU2021303440A1 (en) 2023-02-02
AU2021303440B2 true AU2021303440B2 (en) 2026-07-30

Family

ID=71607883

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021303440A Active AU2021303440B2 (en) 2020-07-07 2021-07-06 1-(1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl)-pyrrolidine-2-carbonitrile

Country Status (19)

Country Link
US (1) US12459891B2 (cg-RX-API-DMAC7.html)
EP (1) EP4178945B1 (cg-RX-API-DMAC7.html)
JP (1) JP7628716B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230035604A (cg-RX-API-DMAC7.html)
CN (1) CN117545738A (cg-RX-API-DMAC7.html)
AU (1) AU2021303440B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023000335A2 (cg-RX-API-DMAC7.html)
CA (1) CA3185064A1 (cg-RX-API-DMAC7.html)
ES (1) ES2997164T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241527T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068953T2 (cg-RX-API-DMAC7.html)
IL (1) IL299035B2 (cg-RX-API-DMAC7.html)
MA (1) MA60250B1 (cg-RX-API-DMAC7.html)
MX (1) MX2023000261A (cg-RX-API-DMAC7.html)
RS (1) RS66215B1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400460T1 (cg-RX-API-DMAC7.html)
TW (1) TWI893162B (cg-RX-API-DMAC7.html)
WO (1) WO2022008477A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202213708B (cg-RX-API-DMAC7.html)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014072498A1 (en) * 2012-11-12 2014-05-15 Universitat De Barcelona 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159938A (en) 1994-11-21 2000-12-12 Cortech, Inc. Serine protease inhibitors comprising α-keto heterocycles
DE19603510A1 (de) 1996-02-01 1997-08-07 Knoell Hans Forschung Ev Die Verwendung von Terrecyclolsäure A und Terrecyclolsäure A-Derivate als neue Inhibitoren der humanen Prolyl-Oligopeptidase
FI20011466A0 (fi) 2001-07-04 2001-07-04 Orion Corp Prolyylioligopeptidaasia inhiboivaa aktiivisuutta omaavia yhdisteitä, niiden valmistusmenetelmiä ja käyttö
FI20030014A0 (fi) 2003-01-03 2003-01-03 Orion Corp Prolyylioligopeptidaasia inhiboivaa aktiivisuutta omaavia yhdisteitä
FI20031018A0 (fi) 2003-07-04 2003-07-04 Orion Corp Parannus aivovammasta toipumiseen
WO2005027934A1 (ja) 2003-09-24 2005-03-31 Nippon Kayaku Kabushiki Kaisha プロリルオリゴペプチダーゼ阻害剤
US7667044B2 (en) 2003-11-03 2010-02-23 Probiodrug Ag Compounds for the treatment of neurological disorders
ES2302473B1 (es) 2006-12-22 2009-06-12 Universidad De Barcelona Agente terapeutico para el tratamiento del desorden afectivo bipolar en mamiferos.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014072498A1 (en) * 2012-11-12 2014-05-15 Universitat De Barcelona 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives

Also Published As

Publication number Publication date
TW202216689A (zh) 2022-05-01
HUE068953T2 (hu) 2025-02-28
WO2022008477A1 (en) 2022-01-13
ES2997164T3 (en) 2025-02-14
RS66215B1 (sr) 2024-12-31
IL299035A (en) 2023-02-01
US20230250058A1 (en) 2023-08-10
EP4178945A1 (en) 2023-05-17
IL299035B2 (en) 2026-07-01
JP2023533932A (ja) 2023-08-07
SMT202400460T1 (it) 2025-01-14
US12459891B2 (en) 2025-11-04
EP4178945C0 (en) 2024-08-28
TWI893162B (zh) 2025-08-11
KR20230035604A (ko) 2023-03-14
EP4178945B1 (en) 2024-08-28
JP7628716B2 (ja) 2025-02-12
ZA202213708B (en) 2024-04-24
CA3185064A1 (en) 2022-01-13
BR112023000335A2 (pt) 2023-01-31
AU2021303440A1 (en) 2023-02-02
MA60250B1 (fr) 2024-11-29
CN117545738A (zh) 2024-02-09
MX2023000261A (es) 2023-04-13
HRP20241527T1 (hr) 2025-01-03
IL299035B1 (en) 2026-03-01